Antiplatelet and anticoagulant use after myocardial infarction

  title={Antiplatelet and anticoagulant use after myocardial infarction},
  author={G. T. Almony and J. Lefkovits and E. Topol},
  journal={Clinical Cardiology},
  • G. T. Almony, J. Lefkovits, E. Topol
  • Published 1996
  • Medicine
  • Clinical Cardiology
  • Coronary thrombosis leading to myocardial infarction is a complex process involving the interaction of the arterial wall, the coagulation cascade, and platelets. Increased understanding of the molecular biology of thrombosis has prompted an evolution in antithrombotic therapy, from the early use of warfarin following myocardial infarction to agents targeting specific receptors or modulators in the thrombotic process. The complexity of thrombosis allows for numerous sites of pharmacologic… CONTINUE READING
    23 Citations

    Topics from this paper

    Unmet therapeutic needs in the management of acute ischemia.
    • H. White
    • Medicine
    • The American journal of cardiology
    • 1997
    • 21
    Pharmacologic therapies after myocardial infarction.
    • 20
    Update on acute coronary syndromes and implications for therapy
    • G. Brogan
    • Medicine
    • Expert opinion on investigational drugs
    • 2003
    • 3
    • Highly Influenced
    Clinical pharmacology of eptifibatide.
    • 208
    • PDF
    Bench to bedside: pathophysiology of acute coronary syndromes and implications for therapy.
    • G. Brogan
    • Medicine
    • Academic emergency medicine : official journal of the Society for Academic Emergency Medicine
    • 2002
    • 14


    Aspirin as an antiplatelet drug.
    • C. Patrono
    • Medicine
    • The New England journal of medicine
    • 1994
    • 896
    Selective thrombin inhibitors: the next generation of anticoagulants.
    • 22